Clinical Trial Update: Characterization of Baseline Biomarker Variability in Participants With Hepatocellular Carcinoma (MK-0000-215) [Phase 1]

View source ↗

Summary

Phase 1 study MK-0000-215 characterizes baseline biomarker variability in participants with hepatocellular carcinoma; the trial was terminated and results were …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• MK-0000-215

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hepatocellular Carcinoma | Phase 1 | Status: TERMINATED | Results posted: 2013-10-28